CLINICAL TRIALS PROFILE FOR VERICIGUAT

All Clinical Trials for VERICIGUAT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02617550 ↗	Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients	Completed	Merck Sharp & Dohme Corp.	Phase 1	2015-11-01	This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
NCT02617550 ↗	Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients	Completed	Bayer	Phase 1	2015-11-01	This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
NCT02861534 ↗	A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)	Completed	Bayer	Phase 3	2016-09-20	This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
NCT02861534 ↗	A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)	Completed	Canadian VIGOUR Centre	Phase 3	2016-09-20	This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
NCT02861534 ↗	A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)	Completed	Duke Clinical Research Institute	Phase 3	2016-09-20	This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
NCT02861534 ↗	A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2016-09-20	This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Clinical Trial Conditions for VERICIGUAT

Condition Name

Condition Name for VERICIGUAT
Intervention	Trials
Heart Failure	12
Chronic Heart Failure With Reduced Ejection Fraction	4
Coronary Artery Disease	3
Heart Failure With Reduced Ejection Fraction	2

Condition MeSH

Condition MeSH for VERICIGUAT
Intervention	Trials
Heart Failure	17
Myocardial Ischemia	3
Coronary Disease	3
Coronary Artery Disease	3

Clinical Trial Locations for VERICIGUAT

Trials by Country

Trials by Country for VERICIGUAT
Location	Trials
United States	54
Germany	26
Japan	16
Spain	11
Italy	9

Trials by US State

Trials by US State for VERICIGUAT
Location	Trials
Indiana	4
Maryland	3
Virginia	3
Texas	3
Florida	3

Clinical Trial Progress for VERICIGUAT

Clinical Trial Phase

Clinical Trial Phase for VERICIGUAT
Clinical Trial Phase	Trials
PHASE4	3
PHASE2	3
PHASE1	1

Clinical Trial Status

Clinical Trial Status for VERICIGUAT
Clinical Trial Phase	Trials
Completed	9
Not yet recruiting	9
Recruiting	6

Clinical Trial Sponsors for VERICIGUAT

Sponsor Name

Sponsor Name for VERICIGUAT
Sponsor	Trials
Bayer	14
Merck Sharp & Dohme Corp.	9
Merck Sharp & Dohme LLC	5

Sponsor Type

Sponsor Type for VERICIGUAT
Sponsor	Trials
Industry	28
Other	23
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Vericiguat

Last updated: November 1, 2025

Introduction

Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, has garnered significant attention in recent years for its potential in treating chronic heart failure (CHF), particularly following evidence of improving clinical outcomes in patients with reduced ejection fraction (HFrEF). Developed by Bayer AG, Vericiguat's journey through clinical trials and its projected market trajectory reflect growing interest in novel heart failure therapies amid evolving regulatory landscapes and demographic shifts.

Clinical Trials Update

Phase III VICTORIA Trial: The Landmark Study

The pivotal V ictoria trial, completed in 2020, investigated Vericiguat's efficacy in reducing cardiovascular death and heart failure hospitalization among adults with symptomatic chronic HFrEF and elevated natriuretic peptide levels. Enrolling over 5,050 patients, the trial demonstrated a significant 10% relative risk reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization (hazard ratio [HR]: 0.90; 95% CI: 0.82–0.98; p=0.02) compared to placebo.

Key Outcomes

• The benefits were consistent across subgroups, notably in high-risk patients with recent decompensation episodes.
• The safety profile was comparable to placebo, with no unexpected adverse effects, endorsing Vericiguat’s tolerability.
• The trial outcomes led to regulatory submissions in major markets, with FDA approval in January 2021 for reducing cardiovascular death and heart failure hospitalization in patients with chronic HFrEF who have had a recent worsening event.

Ongoing and Future Trials

• VITALITY-HFpEF (Phase III): Targeting patients with heart failure with preserved ejection fraction (HFpEF), this trial assesses Vericiguat's efficacy in a different heart failure phenotype. Results remain pending, but positive outcomes could expand Vericiguat’s indication spectrum.
• Post-approval Real-world Studies: Bayer and collaborating institutions are conducting observational studies to monitor long-term safety and effectiveness outside controlled trial environments, critical for clinical adoption and reimbursement decisions.

Market Analysis

Current Market Landscape

The global heart failure therapeutics market exceeds USD 15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of approximately 7% through 2030[1]. The existing treatment paradigm primarily centers around neurohormonal antagonists, including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists. Despite abundant options, unmet needs persist, especially for high-risk populations vulnerable to hospitalization and mortality.

Competitive Positioning of Vericiguat

Vericiguat distinguishes itself by targeting the NO-sGC-cGMP pathway, a novel mechanism to improve endothelial function, mitigate oxidative stress, and promote vasodilation—addressing pathophysiological aspects unmodulated by traditional agents.

• Advantages:
  • Demonstrated efficacy in preventing recurrent HF hospitalizations.
  • Favorable safety profile, allowing use in high-risk, frail populations.
  • Potential to combine with standard therapies without significant drug-drug interactions.
• Limitations:
  • Restricted current indication primarily to patients with recent decompensation.
  • Competition from established agents, including sacubitril/valsartan and SGLT2 inhibitors, which also reduce HF hospitalizations and mortality.

Market Potential and Revenue Projections

The potential addressable market includes approximately 26 million heart failure patients globally, with roughly 50% classified as HFrEF[2]. Bayer estimates about 2-3 million eligible patients in high-income regions alone.

• Initial Adoption: Limited to high-risk post-worsening patients; expected exponential growth as clinical confidence solidifies.
• Long-term Outlook: If ongoing trials like VITALITY-HFpEF demonstrate positive data, Vericiguat could capture a share in HFpEF, expanding market potential.

Key Influencing Factors

• Regulatory Approvals: Beyond the U.S., approvals in Europe, Asia, and other markets are decisive for growth. Bayer's targeted submissions and subsequent expansions could accelerate adoption.
• Reimbursement Dynamics: Payers' recognition of Vericiguat’s cost-effectiveness, especially in reducing hospitalizations, will influence market penetration.
• Physician Adoption: Clinical guideline incorporation and physician familiarity will be critical, especially with competing drugs.

Market Projections

• 2023-2025: Projected global Vericiguat sales of USD ~300–500 million, driven by initial adoption in post-worsening HFrEF.
• 2026-2030: With confirmed efficacy in broader populations and potential approval for HFpEF, sales could reach USD 1–2 billion annually, contingent upon regulatory success and formulary placements[3].

Regulatory and Commercial Outlook

• The positive pivotal trial results and FDA approval establish a solid foundation.
• Bayer’s ongoing efforts to demonstrate benefits in diverse heart failure populations suggest sustained investment.
• Competitive landscape remains dynamic, but Vericiguat’s unique mechanism grants it a niche role.

Key Challenges

• Demonstrating superior or additive benefit over existing therapies.
• Overcoming healthcare system inertia and physician skepticism.
• Managing pricing strategies to ensure reimbursement while maximizing revenue.

Key Takeaways

• Vericiguat’s clinical trial success positions it as a promising therapy for high-risk HFrEF patients, with potential expansion into HFpEF pending further evidence.
• The market for heart failure therapies remains large and competitive, but Vericiguat benefits from its novel mechanism and favorable safety profile.
• Regulatory approvals and real-world evidence will be pivotal to expanding its global footprint.
• Revenue growth hinges on clinical acceptance, cost-effectiveness, and demonstration of long-term outcomes.
• Bayer’s strategic positioning and ongoing research could establish Vericiguat as a cornerstone therapy for specific heart failure segments.

FAQs

1. What is the primary mechanism of action for Vericiguat?
Vericiguat stimulates soluble guanylate cyclase (sGC), enhancing cyclic GMP production, leading to vasodilation, reduced oxidative stress, and improved cardiac and vascular function—counteracting the NO-sGC-cGMP pathway impairment in heart failure.

2. How did the VICTORIA trial influence regulatory decisions?
The VICTORIA trial provided robust evidence of Vericiguat’s efficacy in reducing cardiovascular death and hospitalizations in high-risk HFrEF patients, leading to FDA approval in January 2021 and similar regulatory submissions elsewhere.

3. Can Vericiguat be used in heart failure with preserved ejection fraction (HFpEF)?
Pending results from ongoing Phase III trials like VITALITY-HFpEF, regulatory approval and clinical use in HFpEF remain prospective. If positive, this could significantly expand Vericiguat’s market.

4. What are the main competitors for Vericiguat in the heart failure market?
Main competitors include guideline-recommended therapies such as sacubitril/valsartan, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), and other novel agents targeting different pathophysiological pathways.

5. What is the outlook for Vericiguat’s long-term market success?
With ongoing evidence generation, regulatory expansion, and clinical integration, Vericiguat has substantial growth potential, especially if it demonstrates benefits across diverse heart failure cohorts and proves cost-effective.

---

Sources:
[1] Global Heart Failure Drugs Market Report, 2022
[2] American Heart Association, Heart Disease and Stroke Statistics, 2022
[3] Bayer AG, Corporate Reports and Market Projections, 2023